NCT01879345View on ClinicalTrials.gov

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions

Epilepsy

Interventions

DRUG

BIA 2-093 - 1800 mg (Group 1)

3 tablets of BIA 2-093

DRUG

BIA 2-093 - 2400 mg (Group 2)

4 tablets of BIA 2-093 600 mg

DRUG

Placebo

placebo tablets

Trial Locations (1)

4745-457

Human Pharmacology Unit - BIAL - Portela & Ca, S.A., Trofa

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT01879345 - A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers | Biotech Hunter | Biotech Hunter